We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Sex Hormone–Binding Globulin Is a Biomarker for Cardiovascular Disease Risk Independent of Total Testosterone Concentration

By LabMedica International staff writers
Posted on 03 Jan 2022
Print article
Image: Crystallographic structure of sex hormone binding globulin (SHBG) (Photo courtesy of Wikimedia Commons)
Image: Crystallographic structure of sex hormone binding globulin (SHBG) (Photo courtesy of Wikimedia Commons)
The blood protein sex hormone–binding globulin (SHBG) has been shown to be a biomarker that predicts greater risk of myocardial infarction and lower risk of ischemic stroke and heart failure in men between the ages of 40 and 69.

Investigators at University of Western Australia (Perth) conducted a study to analyze associations of serum total testosterone and SHBG with incident cardiovascular events in men. Testosterone circulates in the bloodstream, with about 54% loosely bound to serum albumin and about 44% bound tightly to SHBG. Only a very small fraction (1 to 2%) is unbound, or "free," and thus biologically active and able to enter a cell and activate its receptor. Thus, bioavailability of sex hormones is influenced by the level of SHBG.

For this study, the investigators analyzed serum samples obtained from 210,700 men aged 40 to 69 for a period of nine years. During this time, outcomes of incident myocardial infarction (MI), hemorrhagic stroke (HS), ischemic stroke (IS), heart failure (HF), and major adverse cardiovascular events (MACE) were observed and associated with measured levels of testosterone and SHBG and calculated levels of free testosterone.

Results revealed that 4.2% (8790) of the men had an incident cardiovascular event during the nine year course of the study. Lower testosterone concentrations were not associated with incident MI, HS, IS, HF, or MACE after adjustment for key variables. The incidence of MACE was significantly lower for men with lower calculated free testosterone values. Lower SHBG concentrations were associated with higher incidence of MI and lower incidence of IS and HF, but not with HS or MACE.

These results allowed the investigators to conclude, "Men with lower SHBG concentrations have higher risk for MI but lower risk for HF, indicating a role for SHBG as a biomarker for various cardiovascular risks, independently of total testosterone concentrations."

The study was published in the December 28, 2021, online edition of the journal Annals of Internal Medicine.

Related Links:
University of Western Australia

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: The Aperio GT 450 DX has received US FDA 510(k) clearance (Photo courtesy of Leica Biosystems)

Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization

Digital pathology is rapidly becoming a key aspect of modern healthcare, transforming the practice of pathology as laboratories worldwide adopt this advanced technology. Digital pathology systems allow... Read more